Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
8.45
+0.09 (1.08%)
Nov 21, 2024, 11:09 AM EST - Market open
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 133 employees as of December 31, 2023. The number of employees increased by 10 or 8.13% compared to the previous year.
Employees
133
Change (1Y)
10
Growth (1Y)
8.13%
Revenue / Employee
$112,594
Profits / Employee
-$897,662
Market Cap
519.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Community Health Systems | 61,000 |
| Fulgent Genetics | 1,184 |
| Talkspace | 472 |
| Pharming Group | 382 |
| SI-BONE | 344 |
| ProKidney | 163 |
| Terns Pharmaceuticals | 66 |
| GH Research | 49 |
GLUE News
- 23 days ago - This Biotech Stock Has Doubled Its Value Today—Here's Why - Investopedia
- 24 days ago - Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - GlobeNewsWire
- 5 months ago - Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 - GlobeNewsWire
- 5 months ago - Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis - GlobeNewsWire
- 6 months ago - Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire